2,5-二甲基-3-苯基噻吩 | 5682-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2,5-二甲基-3-苯基噻吩
• 英文名称: 2,5-dimethyl-3-phenylthiophene
• 英文别名: 2.5-Dimethyl-3-phenyl-thiophen；Thiophene, 2,5-dimethyl-3-phenyl-
• CAS: 5682-08-6
• 化学式: C₁₂H₁₂S
• mdl: MFCD18451827
• 分子量: 188.293
• InChiKey: PRFVRPHTGGFNSR-UHFFFAOYSA-N

物化性质

• 沸点：
  236.2±9.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  3-iodo-2,5-dimethyl-4-phenyl-thiophene 以35%的产率得到
  参考文献：
  名称：

  GRONOWITZ S.; FREJD T., ACTA CHEM. SCAND. , 1976, B 30, NO 6, 485-490

  摘要：

  DOI：

文献信息

• [EN] S1P RECEPTORS MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010042998A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  该发明涉及具有S1P受体调节活性的新化合物，最好具有对癌细胞和其他细胞类型具有凋亡活性和/或抗增殖活性。此外，该发明涉及包含该发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如癌症。该发明的另一个方面涉及使用包含该发明中至少一种化合物的药物制备药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如癌症。
• Tris-NHC-propagated self-supported polymer-based Pd catalysts for heterogeneous C–H functionalization
  作者：Tanmoy Mandal、Tapas Kumar Dutta、Sunit Mohanty、Joyanta Choudhury

  DOI：10.1039/d1cc04429j

  日期：——

  imidazolium-containing mesoporous coordination polymer and organic polymer-based platforms were successfully exploited to develop single-site heterogenized Pd–NHC catalysts for oxidative arene/heteroarene C–H functionalization reactions. The catalysts were efficient in directed arene halogenation, and nondirected arene and heteroarene arylation reactions. High catalytic activity, excellent heterogeneity and

  成功地利用三维传播的含咪唑鎓介孔配位聚合物和基于有机聚合物的平台来开发用于氧化芳烃/杂芳烃 C-H 功能化反应的单点多相 Pd-NHC 催化剂。该催化剂在定向芳烃卤化、非定向芳烃和杂芳烃芳基化反应中是有效的。这些系统提供了高催化活性、优异的异质性和可回收性，使它们成为多相 C-H 功能化领域的有希望的候选者，而高效催化剂仍然稀缺。
• Pd/C as a Catalyst for Completely Regioselective CH Functionalization of Thiophenes under Mild Conditions
  作者：Dan-Tam D. Tang、Karl D. Collins、Johannes B. Ernst、Frank Glorius

  DOI：10.1002/anie.201309305

  日期：2014.2.10

  The completely C3‐selective arylation of thiophenes and benzo[b]thiophenes was achieved by using Pd/C as a heterogeneous catalyst without ligands or additives under mild reaction conditions. The practicability of this transformation is demonstrated by notable functional group tolerance and the insensitivity of the reaction to H2O and air. This method is also applicable to nitrogen‐ and oxygen‐containing

  通过在温和的反应条件下使用Pd / C作为不带配体或添加剂的非均相催化剂，可以实现噻吩和苯并[ b ]噻吩的完全C3选择性芳基化。该转化的实用性通过显着的官能团耐受性和反应对H 2 O和空气的不敏感性得到证明。该方法也适用于含氮和氧的杂环，产生相应的C2芳基化产物。三相试验以及汞中毒和热过滤试验表明，催化活性物质在性质上是异质的。
• Pd-Catalyzed β-Selective Direct C–H Bond Arylation of Thiophenes with Aryltrimethylsilanes
  作者：Kenji Funaki、Tetsuo Sato、Shuichi Oi

  DOI：10.1021/ol3029109

  日期：2012.12.21

  Direct arylation of thiophenes and benzothiophenes with aryltrimethylsilanes was effectively catalyzed by PdCl2(MeCN)2 in the presence of CuCl2 as an oxidant. The reaction preferentially occurred at the β-position of both thiophenes and benzothiophenes.

  在CuCl 2作为氧化剂的存在下，PdCl 2（MeCN）2有效地催化了噻吩和苯并噻吩与芳基三甲基硅烷的直接芳基化。该反应优选在噻吩和苯并噻吩的β-位置发生。
• NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：US20200347046A1

  公开（公告）日：2020-11-05

  A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP 4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.

  以下通用公式（1）所代表的新化合物，或其盐，具有优越的EP4受体激动剂活性，以及含有该化合物或其盐作为活性成分的药物，可用于促进骨生成、治疗和/或促进骨折愈合等用途。